TCH-005 Developing a Safe System to Prescribe, Prepare and Administer Cytostatic Drugs

Abstract

In the period under review, 85.9 g of bevacizumab, 37.5 g of cetuximab and 43.8 g trastuzumab were prepared using material that would previously have been discarded. This provided considerable saving for the three drugs (€29,893) which corresponds to approximately €90,000 per year. Conclusions The centralised system and the use of APOTE-CAchemo is successful both in terms of patient and operator safety and cost benefit for the Hospital. No conflict of interest. Developing a Safe SyStem to preScribe, prepare anD aDminiSter cytoStatic DrugS